Patents by Inventor Fionn O'Hara

Fionn O'Hara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210277020
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using the compounds and methods of determining the monoacylglycerol lipase (MAGL) inhibitory activity of the compounds.
    Type: Application
    Filed: February 11, 2021
    Publication date: September 9, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lilli ANSELM, Joerg BENZ, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Dominik HEER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Fionn O`HARA, Hans RICHTER
  • Publication number: 20210269452
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: May 9, 2021
    Publication date: September 2, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Patent number: 11034699
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: June 15, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Publication number: 20210107920
    Abstract: The invention provides new heterocyclic compounds having the general formula (Ic) wherein A, L, X, m, n and R20 to R23 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 18, 2020
    Publication date: April 15, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Dennis Jul HANSEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Fionn O'HARA, Hans RICHTER, Martin RITTER, Satoshi TSUCHIYA, Rui CHEN
  • Publication number: 20210107921
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, Q, U, V, W, X, Z, m, n, and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 21, 2020
    Publication date: April 15, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Steven Paul HANLON, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Martin KURATLI, Guofu LIU, Fionn O`HARA, Hans RICHTER, Martin RITTER
  • Publication number: 20210094972
    Abstract: The invention provides new heterocyclic compounds having the general formulae (Ia) and (Ib) wherein A, B, and L are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 22, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
  • Publication number: 20210094973
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L1, X, m, n and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 22, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER
  • Publication number: 20210094971
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, X, R1, R2, R3 and R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 4, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Uwe GRETHER, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O`HARA, Hans RICHTER
  • Publication number: 20210094943
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and RI to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: September 10, 2020
    Publication date: April 1, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Carsten KROLL, Bernd KUHN, Rainer E. MARTIN, Fionn O`HARA, Bernd PUELLMANN, Hans RICHTER, Martin RITTER
  • Publication number: 20200308190
    Abstract: The invention provides new heterocyclic compounds having the general formula wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: April 9, 2020
    Publication date: October 1, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Charles BELL, Joerg BENZ, Luca GOBBI, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Buelent KOCER, Carsten KROLL, Bernd KUHN, Marius Daniel Rinaldo LUTZ, Fionn O'HARA, Hans RICHTER, Martin RITTER, Didier ROMBACH, Martin KURATLI
  • Publication number: 20200299277
    Abstract: The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: March 23, 2020
    Publication date: September 24, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Uwe GRETHER, Benoit HORNSPERGER, Bernd KUHN, Hans RICHTER, Buelent KOCER, Fionn O'HARA, Martin RITTER, Satoshi TSUCHIYA, Ludovic COLLIN, Simon E. JOHNSON, Charles BELL
  • Publication number: 20200291033
    Abstract: The present invention relates to compounds of formula I wherein L is a bond, a triple bond, —C(O)NH— or —NHC(O)—; R1 is phenyl or a five or six-membered heteroaryl group, optionally substituted by lower alkyl, lower alkyl substituted by halogen or lower alkoxy substituted by halogen; R2 is fluoro; R3 is fluoro or chloro; R4 is hydrogen, lower alkyl, halogen, lower alkyl substituted by hydroxy, S(O)2CH3, or is a five or six-membered heteroaryl group or a heterocycloalkyl group, which are optionally substituted by lower alkyl, hydroxy or ?O; R5 and R6 are both methyl and the dotted line is a bond, or R5 and R6 are both methyl and the dotted line is nothing, or one of R5 and R6 is hydrogen and the other is methyl, and the dotted line is nothing; or to a pharmaceutically acceptable salt or acid addition salt, to all possible tautomeric forms, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
    Type: Application
    Filed: February 13, 2020
    Publication date: September 17, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg JAESCHKE, Fionn O'HARA, Eric VIEIRA
  • Publication number: 20200255440
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara BIEMANS, Georg JAESCHKE, Antonio RICCI, Daniel RUEHER, Fionn O'HARA
  • Publication number: 20190144458
    Abstract: The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 16, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: BARBARA BIEMANS, GEORG JAESCHKE, ANTONIO RICCI, DANIEL RUEHER, FIONN O'HARA
  • Publication number: 20190119290
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 25, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Patent number: 10189848
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: January 29, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Patent number: 10065956
    Abstract: The present invention relates to compounds that may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2. Compounds of formula I are representative, where substituents are defined herein: or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: September 4, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Jean-Marc Plancher, Antonio Ricci, Daniel Rueher, Eric Vieira, Fionn O'Hara
  • Patent number: 10011607
    Abstract: The present invention relates to compounds of formula I wherein R1 is hydrogen, F or Cl; L is a bond or lower alkylene; R2 is —(CH2)nO-lower alkyl, lower alkyl substituted by halogen, —(CH2)nC(O)O-lower alkyl, phenyl substituted by lower alkyl or halogen, or is a 5 or 6-membered heteroaryl group, selected from pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, imidazolyl, pyrazolyl or triazolyl, which are optionally substituted by lower alkyl, halogen, lower alkoxy, ?O, benzyloxy, cycloalkyloxy, hydroxy, cyano, lower alkyl substituted by halogen, or by —(CH2)nO-lower alkyl; n is 1, 2 or 3; R3 is hydrogen, lower alkyl or —(CH2)nO-lower alkyl; R4 is phenyl, pyridinyl or pyrimidinyl, optionally substituted by F; Y is CF or CCl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomers thereof.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: July 3, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Georg Jaeschke, Fionn O'Hara, Jean-Marc Plancher, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Publication number: 20180134721
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 17, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Publication number: 20180127429
    Abstract: The present invention relates to compounds of formula I wherein R1 is hydrogen, F or Cl; L is a bond or lower alkylene; R2 is —(CH2)nO-lower alkyl, lower alkyl substituted by halogen, —(CH2)nC(O)O-lower alkyl, phenyl substituted by lower alkyl or halogen, or is a 5 or 6-membered heteroaryl group, selected from pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, imidazolyl, pyrazolyl or triazolyl, which are optionally substituted by lower alkyl, halogen, lower alkoxy, ?O, benzyloxy, cycloalkyloxy, hydroxy, cyano, lower alkyl substituted by halogen, or by —(CH2)nO-lower alkyl; n is 1, 2 or 3; R3 is hydrogen, lower alkyl or —(CH2)nO-lower alkyl; R4 is phenyl, pyridinyl or pyrimidinyl, optionally substituted by F; Y is CF or CCl; or to a pharmaceutically acceptable salt or acid addition salt, to a racemic mixture, or to its corresponding enantiomer and/or optical isomer and/or stereoisomers thereof.
    Type: Application
    Filed: January 10, 2018
    Publication date: May 10, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Georg JAESCHKE, Fionn O'HARA, Jean-Marc PLANCHER, Antonio RICCI, Daniel RUEHER, Eric VIEIRA